Analytical Data
-
Gene name
PCDHgA9
- Application
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q91XX9
-
Expression Region
Gly30~Leu295
-
Molecular Weight
35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PCDHgA9 (Protocadherin gamma A9) is a member of the protocadherin family, which plays crucial roles in cell adhesion, neuronal development, and synaptic functioning. This protein is particularly significant in the context of the central nervous system, where it is involved in establishing and maintaining neural networks. Research has increasingly indicated that protocadherins, including PCDHgA9, are linked to various neurological disorders, such as schizophrenia and autism spectrum disorders, making them vital targets for therapeutic interventions. The recombinant expression of PCDHgA9 allows for in-depth studies of its structural properties, functional mechanisms, and interactions with other cellular components. Furthermore, understanding the specific signaling pathways and cellular contexts in which PCDHgA9 operates can reveal its role in both normal physiology and in pathological conditions. As advancements in molecular biology techniques improve, the generation of recombinant PCDHgA9 facilitates high-throughput screenings and the development of novel drugs aimed at modulating its activity, potentially providing new avenues for treatment of diseases associated with its dysregulation. Thus, the study of PCDHgA9 as a recombinant protein not only enhances our fundamental understanding of protocadherins but also holds promise for innovative therapeutic strategies in neuroscience.
